182 related articles for article (PubMed ID: 18086344)
1. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
Furman RR; Hoelzer D
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
Gandhi V; Balakrishnan K
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
[TBL] [Abstract][Full Text] [Related]
3. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Korycka A; Błoński JZ; Robak T
Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
Balakrishnan K; Ravandi F; Bantia S; Franklin A; Gandhi V
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):458-66. PubMed ID: 23773454
[TBL] [Abstract][Full Text] [Related]
5. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
6. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
7. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
[TBL] [Abstract][Full Text] [Related]
8. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
[TBL] [Abstract][Full Text] [Related]
9. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.
Kicska GA; Long L; Hörig H; Fairchild C; Tyler PC; Furneaux RH; Schramm VL; Kaufman HL
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4593-8. PubMed ID: 11287638
[TBL] [Abstract][Full Text] [Related]
10. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
Larson RA
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
[TBL] [Abstract][Full Text] [Related]
11. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.
Ravandi F; Gandhi V
Expert Opin Investig Drugs; 2006 Dec; 15(12):1601-13. PubMed ID: 17107284
[TBL] [Abstract][Full Text] [Related]
12. The transition state analog inhibitor of Purine Nucleoside Phosphorylase (PNP) Immucillin-H arrests bone loss in rat periodontal disease models.
Deves C; de Assunção TM; Ducati RG; Campos MM; Basso LA; Santos DS; Batista EL
Bone; 2013 Jan; 52(1):167-75. PubMed ID: 23026564
[TBL] [Abstract][Full Text] [Related]
13. [Purine nucleoside phosphorylase (PNP)].
Sakiyama T
Nihon Rinsho; 1996 Dec; 54(12):3220-5. PubMed ID: 8976095
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
[TBL] [Abstract][Full Text] [Related]
15. Forodesine: review of preclinical and clinical data.
Al-Kali A; Gandhi V; Ayoubi M; Keating M; Ravandi F
Future Oncol; 2010 Aug; 6(8):1211-7. PubMed ID: 20799866
[TBL] [Abstract][Full Text] [Related]
16. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part I.
Kamath VP; Xue J; Juarez-Brambila JJ; Morris CB; Ganorkar R; Morris PE
Bioorg Med Chem Lett; 2009 May; 19(10):2624-6. PubMed ID: 19386498
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of purine nucleoside phosphorylase: effects of 9-deazapurine ribonucleosides and synthesis of 5'-deoxy-5'-iodo-9-deazainosine.
Stoeckler JD; Ryden JB; Parks RE; Chu MY; Lim MI; Ren WY; Klein RS
Cancer Res; 1986 Apr; 46(4 Pt 1):1774-8. PubMed ID: 3081256
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part II.
Kamath VP; Xue J; Juarez-Brambila JJ
Bioorg Med Chem Lett; 2009 May; 19(10):2627-9. PubMed ID: 19386496
[TBL] [Abstract][Full Text] [Related]
20. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.
Schramm VL
Biochim Biophys Acta; 2002 Jul; 1587(2-3):107-17. PubMed ID: 12084452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
